Seven-Country Market for Therapies to Treat Erectile Dysfunction Will Approach 4 Billion by 2008, Reports Decision Resources, Inc.
WALTHAM, Mass., April 26 /PRNewswire/ -- In 1998, erectile dysfunction (ED) affected more than 75 million men in the world's seven major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan), and prevalence is expected to exceed 90 million in 2008. The 1998 approval of Pfizer's Viagra, the first oral therapy approved for the treatment of ED, has revolutionized the ED treatment market by stimulating a dramatic rise in both the diagnosed and drug-treated populations of ED sufferers. Viagra also catapulted sales of erectile dysfunction therapies into the stratosphere, more than quadrupling the size of the ED market in just one year. Although Viagra addresses nearly all of the needs of the ED patient population, opportunity does exist for new, fast-acting, oral pharmacotherapies with greater specificity and minimal side effects.
Erectile Dysfunction is a new study from Decision Resources, Inc., that provides a comprehensive evaluation of this condition. The report, which is based on in-depth interviews with opinion-leading physicians in each country, contains detailed information on epidemiology, medical practice, and current and emerging therapies. The study also includes an in-depth unmet needs analysis, an evaluation of economic issues, and sales forecasts for therapies to treat ED in the seven major markets through 2008. We forecast that sales of therapies to treat erectile dysfunction in the seven major markets will nearly quadruple in size between 1998 and 2008, increasing from more than $880 million to nearly $4 billion.
This report is part of Mosaic, a series of studies on timely topics, focusing on medical indications that are distinguished by major unmet need or significant changes in medical practice. The report is priced at $12,000. For more detailed report information, contact Jean Carbone, Director, Research Publications, 781-487-3737 (telephone), 781-487-3735 (fax), or carbone@dresources.com (e-mail). Decision Resources, Inc., Bay Colony Corporate Center, 1100 Winter Street, Waltham, MA 02451. In Europe, contact Ms. Vera Bisegna, +32-2-351-1079 (telephone), +32-2-351-2347 (fax), or vbisegna@compuserve.com (e-mail). In Japan, contact Ms. Makiko Yoshimoto, +81-3-5401-2615 (telephone), +81-3-5401-2617 (fax), or makiko@bl.mmtr.or.jp (e-mail).
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., and employee-owned since 1990, Decision Resources, Inc., has provided strategic information services for more than 25 years, assessing industry trends in the international health care and pharmaceutical industries. Drawing on a closely linked international network of experts, Decision Resources, Inc., offers its clients the most comprehensive analyses of therapy markets available.
SOURCE Decision Resources, Inc.
CO: Decision Resources, Inc.
ST: Massachusetts
IN: MTC
SU:
04/26/99 09:01 EDT prnewswire.com
|
